The difference between hydroxyurea tablets and Ruxolitinib tablets (Ruxolitinib)

Ruxolitinib and Hydroxyurea are two different drugs used for different diseases and treatment purposes. Ruxolitinib tablets are a targeted therapy drug that reduces inflammation and abnormal cell proliferation by inhibiting the JAK signaling pathway, while hydroxyurea tablets are an anti-tumor and anti-leukemia drug that inhibits the proliferation of abnormal cells by interfering with DNA synthesis.

Ruxolitinib tablets are mainly used to treat specific types of blood diseases, such as myelodysplastic syndrome, primary myelofibrosis, etc., and are administered orally. However, the dosage and usage regimen will vary depending on the type of disease and the patient's condition. Common side effects include thrombocytopenia, anemia, headache, fatigue, etc. Hydroxyurea tablets are widely used to treat hematological malignancies such as leukemia and multiple myeloma, and are also used to treat diseases related to polycythemia. Common side effects include anemia, loss of appetite, nausea, vomiting, etc.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.